Additional Information Patent Expiries of Key Marketed Products Patents covering our products are or may be challenged by third parties.
Generic products may be launched at risk and our patents may be revoked, circumvented or found not to be infringed.
For more information, please see Risk from page 214.
Many of our products are subject to challenges by third parties.
Details of material challenges by third parties can be found in Note 28 to the Financial Statements from page 185.
The expiry dates shown below include granted SPC PTE and or Paediatric Exclusivity periods as appropriate, but do not include projected expiry dates based on pending applications for these exclusivities unless asterisked.
In Europe, the exact SPC situation may vary by country as different Patent Ofces grant SPCs at different rates.
Expiry dates in red relate to new chemical entity or antibody patents, the remaining dates relate to other patents.
A number of our products are subject to generic competition in one or more markets.
Further information can be found in the Geographical Review from page 226.
Aggregate Revenue for 2 US China, Japan and Europe Product Sales Product Sales $m $m Key marketed 1 products Description US China EU Japan 2016 2015 2014 2016 2015 2014 3 4 4 Atacand An angiotensin II antagonist for the expired expired 36 34 44 97 106 169 1st line treatment of hypertension and symptomatic heart failure Brilinta Brilique An oral P2Y12 platelet inhibitor for 2018-2019, 2018-2019, 2018-2024, 2018-2019, 348 240 146 347 268 245 5 acute coronary syndromes ACS 2024, 2021 2021 2024, or extended therapy in high-risk 2021-2030 2021-2027 patients with a history of myocardial infarction MI Bydureon A once-weekly injectable glucagon- 2018-2028 2020-2028 2017-2028 2018-2028 463 482 374 109 90 62 like peptide-1 GLP-1 receptor agonist available as a single-dose tray or a single-dose pen indicated to improve glycaemic control, in adults with Type 2 diabetes Byetta A twice-daily injectable GLP-1 2017-2020 2020 2017-2021 2018-2020 164 209 199 62 86 107 receptor agonist indicated to improve glycaemic control in adults with Type 2 diabetes 6 Crestor A statin for dyslipidaemia and 2018-2022 2020-2021 2017, 2020 2017, 1,223 2,844 2,918 1,698 1,642 1,931  2021-2023 7 Daliresp Daxas An oral PDE4 phosphodiesterase-4 2020, 2023 2019, 2023 2023 134 104 15 inhibitor for adults with severe COPD 2023-2024 to decrease their number of exacerbations US only Duaklir A xed-dose combination of a 2020, 2025, 2020, 2025, 2025, 62 26 8 long-acting muscarinic antagonist 2022-2027 2022-2027 2022-2029 2021-2029 LAMA and a long-acting betaadrenergic receptor agonist 2 LABA for the maintenance treatment of COPD 9 Faslodex An injectable estrogen receptor 2021 2021 2026 438 356 340 311 269 305 antagonist.
It is used for the treatment of hormone receptor positive advanced breast cancer for post-menopausal women whose disease has progressed following treatment with prior endocrine therapy Farxiga Forxiga A selective inhibitor of human 2020, 2026 2020-2023, 2020-2028 2020-2025, 358 229 120 175 121 66 sodium-glucose co-transporter 2 2028 2028 SGLT2 inhibitor indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with Type 2 diabetes AstraZeneca Annual Report and Form 20-F Information 2016 211 Additional Information Patent Expiries of Key Marketed Products continued Aggregate Revenue for 2 US China, Japan and Europe Product Sales Product Sales $m $m Key marketed 1 products Description US China EU Japan 2016 2015 2014 2016 2015 2014 10 11 Iressa An epidermal growth factor 2017 2023 2019, 2023 2018, 2023 23 6 358 396 467 receptor-tyrosine kinase inhibitor EGFR-TKI that acts to block signals for cancer cell growth and survival in advanced non-small cell lung cancer NSCLC Kombiglyze XR Combines saxagliptin Onglyza 2021-2023, 2021, 2025 2021-2026, 145 154 159 and extended release metformin 2025 2025 metformin XR in a once-daily tablet for Type 2 diabetes 8 Komboglyze Combines saxagliptin Onglyza 2021, 2025 2021-2026, 49 48 40 and metformin immediate release 2025 metformin IR in a twice-daily tablet for Type 2 diabetes Lynparza An oral poly ADP-ribose polymerase 2022-2024, 2021-2024, 2021-2029, 2021-2024, 127 70 81 23 PARP inhibitor currently only 2028, 2024-2027 2024-2027 2024-2027 approved as a capsule formulation.
2024-2031 It is approved in the EU for the treatment of adult patients with platinum-sensitive relapsed BRCA-mutated germline and or somatic high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer.
It is approved in the US for the treatment of patients with germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy 2022-2024 90 28 Movantik Moventig A once-daily, peripherally-acting 2022-2027, 2024 2022-2024, 14 mu-opioid receptor antagonist 2028, 2032 2029 approved for the treatment of opioid-induced constipation OIC in adult patients.
Theindication varies by jurisdiction 15 Nexium A proton pump inhibitor used to treat 2018-2020 2018-2019 2018 2018, 526 870 1,821 975 985 1,015 acid-related diseases 2018-2019 12 Onglyza An oral dipeptidyl peptidase 4 2021-2024, 2021, 2025 2021-2025, 231 266 322 119 124 129 DPP-4 inhibitor for Type 2 diabetes 2018-2028 2025 16 17 17 17 Pulmicort An inhaled corticosteroid for 2018-2019 2018 2018 2018 174 200 211 732 662 574 maintenance treatment of asthma Seloken Toprol-XL A beta-blocker once-daily tablet for expired expired expired expired 95 89 91 462 436 438 control of hypertension, heart failure and angina 212 AstraZeneca Annual Report and Form 20-F Information 2016 Additional Information Aggregate Revenue for 2 US China, Japan and Europe Product Sales Product Sales $m $m Key marketed 1 products Description US China EU Japan 2016 2015 2014 2016 2015 2014 18 19 Seroquel XR Generally approved for the treatment 2017 2017 2017 515 716 738 134 201 342 of schizophrenia, bipolar disorder, major depressive disorder and, on a more limited basis, for generalised anxiety disorder 20 21 21 21 Symbicort A combination of an inhaled 2017-2029 2018 2018-2019 2017-2020 1,242 1,520 1,511 1,276 1,375 1,756 corticosteroid and a fast onset LABA for maintenance treatment of asthma and COPD Synagis A humanised MAb used to prevent 2023 2023 2023 325 285 499 352 377 401 serious lower respiratory tract disease caused by respiratory syncytial virus RSV in paediatric patients at high risk of acquiring RSV disease Tagrisso An EGFR-TKI indicated for patients 2032, 2035 2032, 2035 2032, 2035 2032, 2034, 254 15 158 4 with metastatic EGFR T790M 2035 mutation-positive NSCLC Tudorza Eklira A LAMA for the maintenance 2020, 2025, 2020, 2025, 2025, 77 103 84 77 13 Genuair treatment of COPD 2022-2027 2022-2027 2022-2029 2021-2029 Xigduo Combines dapagliozin Farxiga 2020, 2026 2020-2023 2020-2028 2020-2025, 99 32 2 40 21 12 Forxiga, an SGLT2 inhibitor, and 2030 metformin IR, in a twice-daily tablet to improve glycaemic control in adult patients with Type 2 diabetes who are inadequately controlled by metformin alone Zoladex A luteinising hormone-releasing 2022 2021 2021 2021 35 28 26 498 485 544 hormone LHRH agonist used to treat prostate cancer, breast cancer and certain benign gynaecological disorders Date represents expiry of any granted SPC PTE and or Paediatric Exclusivity periods.
1 Expiry in major EU markets.
2 7KH 3URGXFW 6DOHV UHHFWHG DUH RI XURSH 5HJLRQ DV GHQHG LQ 0DUNHW GHQLWLRQV RQ SDJH 3 Atacand HCT in US.
5 7KH SDWHQW ZDV UHYRNHG GXULQJ RSSRVLWLRQ SURFHHGLQJV DW WKH XURSHDQ 3DWHQW 2FH 32 7KH SDWHQWHH KDV DSSHDOHG WKDW GHFLVLRQ 6 A settlement agreement in the US permitted Watson Laboratories, Inc. and Actavis, Inc. together, Watson to begin selling its generic version of Crestor DQG LWV URVXYDVWDWLQ ]LQF SURGXFW IURP b0D 7 There is eight years data exclusivity and two years market exclusivity for Daxas in the EU to 5 July 2020.
8 1RW OHG IRU DSSURYDO LQ 86 9 6HWWOHG ZLWK 6DQGR], QF IRU D OLFHQVHG HQWU GDWH RI 0DUFK 10 In the US, Iressa has seven years orphan drug exclusivity to 13 July 2022.
There is eight years data exclusivity and two years market exclusivity for Iressa in the EU to 24 June 2019.
12 AstraZeneca does not have commercialisation rights.
13 Komboglyze Kombiglyze XR revenue is included in the Onglyza UHYHQXH JXUH 14 3UR6WUDNDQ URXS D VXEVLGLDU RI.
LULQ &R WG LV H[FOXVLYHO OLFHQVHG LQ WKH 8, FHODQG 1RUZD 6ZLW]HUODQG DQG LHFKWHQVWHLQ 15 Licence agreements with Teva and Ranbaxy Pharmaceuticals Inc. and other generic companies allow each to launch a generic version in the US from May 2014, subject to regulatory approval.
16 A licence agreement with Teva permits its ongoing sale in the US of a generic version from December 2009.
The 2018 expiry relates to the Flexhaler device, while the 2019 expiry relates to the formulation in the Flexhaler presentation and also to Respules.
17 The 2018 expiry relates to the formulation in the Turbuhaler presentation and to a process useful for the Respules product.
18 Licence agreements with various generics companies allowed launches of generic versions of Seroquel XR in the US as of 1 November 2016.
20 Patent expiry dates relate to the Symbicort pMDI product.
The six months of paediatric exclusivity that have been granted are not included as they are not yet included in the Orange Book.
21 Patent expiry dates relate to the Symbicort Turbuhaler product.
AstraZeneca Annual Report and Form 20-F Information 2016 213
